Form 4: Pfizer Director Joseph Echevarria Acquires Phantom Stock

Pfizer Inc. director Joseph Echevarria was granted 7,686.539 phantom stock units as part of deferred director compensation.

Summary

• Director Joseph Echevarria acquired 7,686.539 phantom stock units on April 23, 2026.
• The units were granted under the Pfizer Inc. Nonfunded Deferred Compensation and Unit Award Plan for Non-Employee Directors.
• Each unit represents one phantom share of common stock valued at $26.67 per unit.
• The total beneficial ownership following this transaction is 161,084.684 units.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral, routine administrative filing regarding director compensation that does not signal a change in company strategy or financial health.

Positives

• Demonstrates alignment of director interests with long-term shareholder value through equity-based compensation.

Negatives

• None identified.

Risks

• Value of phantom stock units is subject to the future market performance of Pfizer common stock.

Future Outlook

The units are settled in cash or common stock at the director's election following their retirement from the Board of Directors.

Industry Context

StockSavvy.ai notes that this is a routine disclosure of director compensation, common among large-cap pharmaceutical companies to incentivize board members through deferred equity plans.

Comparison to Industry Standards

• The use of phantom stock units for non-employee director compensation is a standard corporate governance practice among S&P 500 companies.
• The structure aligns with typical deferred compensation plans seen at peers like Merck or Bristol-Myers Squibb.

Corporate Governance

Stakeholder Impact

• Minimal impact on shareholders as this is a standard compensation arrangement.

Next Steps

• Settlement of units upon the director's future retirement from the Board.

Key Dates

Keywords

Pfizer, PFE, Form 4, Insider Trading, Director Compensation, Phantom Stock